Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa

dc.contributor.affiliationPontificia Universidad Catolica de Valparaiso
dc.contributor.affiliationUniversidad del Desarrollo
dc.contributor.affiliationUniversidad de Las Americas - Chile
dc.contributor.affiliationUniversidad Andres Bello
dc.contributor.affiliationPontificia Universidad Catolica de Chile
dc.contributor.authorContreras-Gomez, María Jose
dc.contributor.authorW. Martínez, Jose R.
dc.contributor.authorRivas, Lina
dc.contributor.authorRiquelme-Neira, Roberto
dc.contributor.authorUgalde, Juan A.
dc.contributor.authorWozniak, Aniela
dc.contributor.authorGarcia, Patricia
dc.contributor.authorMunita, Jose M.
dc.contributor.authorOlivares-Pacheco, Jorge
dc.contributor.authorAlcalde-Rico, Manuel
dc.date.accessioned2024-09-03T19:19:15Z
dc.date.available2024-09-03T19:19:15Z
dc.date.issued2022-10-03
dc.description.abstractCarbapenem-resistant Pseudomonas aeruginosa (CRPA) is one of the pathogens that urgently needs new drugs and new alternatives for its control. The primary strategy to combat this bacterium is combining treatments of beta-lactam with a beta-lactamase inhibitor. The most used combinations against P. aeruginosa are ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T). Although mechanisms leading to CZA and C/T resistance have already been described, among which are the resistance-nodulation-division (RND) efflux pumps, the role that these extrusion systems may play in CZA, and C/T baseline susceptibility of clinical isolates remains unknown. For this purpose, 161 isolates of non-carbapenemase-producing (Non-CP) CRPA were selected, and susceptibility tests to CZA and C/T were performed in the presence and absence of the RND efflux pumps inhibitor, Phenylalanine-arginine β-naphthylamide (PAβN). In the absence of PAβN, C/T showed markedly higher activity against Non-CP-CRPA isolates than observed for CZA. These results were even more evident in isolates classified as extremely-drug resistant (XDR) or with difficult-to-treat resistance (DTR), where CZA decreased its activity up to 55.2% and 20.0%, respectively, whereas C/T did it up to 82.8% (XDR), and 73.3% (DTR). The presence of PAβN showed an increase in both CZA (37.6%) and C/T (44.6%) activity, and 25.5% of Non-CP-CRPA isolates increased their susceptibility to these two combined antibiotics. However, statistical analysis showed that only the C/T susceptibility of Non-CP-CRPA isolates was significantly increased. Although the contribution of RND activity to CZA and C/T baseline susceptibility was generally low (two-fold decrease of minimal inhibitory concentrations [MIC]), a more evident contribution was observed in a non-minor proportion of the Non-CP-CRPA isolates affected by PAβN [CZA: 25.4% (15/59); C/T: 30% (21/70)]. These isolates presented significantly higher MIC values for C/T. Therefore, we conclude that RND efflux pumps are participating in the phenomenon of baseline susceptibility to CZA and, even more, to C/T. However, the genomic diversity of clinical isolates is so great that deeper analyzes are necessary to determine which elements are directly involved in this phenomenon.
dc.description.sponsorshipAgencia Nacional de Investigacion y Desarrollo (ANID, Chile) through the Millennium Science Initiative/Millennium Initiative for Collaborative Research on Bacterial Resistance, MICROB-R [NCN17-08]; Pfizer Global Medical Grant [67276851]; ANID FONDECYT [3200798]; This study was funded by the Agencia Nacional de Investigacion y Desarrollo (ANID, Chile) through the Millennium Science Initiative/Millennium Initiative for Collaborative Research on Bacterial Resistance, MICROB-R, NCN17-08, ANID FONDECYT No3200798, and Pfizer Global Medical Grant ID #67276851.
dc.format.mimetypeapplication/pdf
dc.identifier.citationFrontiers in Pharmacology, 13, 1007162. https://doi.org/10.3389/fphar.2022.1007162
dc.identifier.doihttps://doi.org/10.3389/fphar.2022.1007162
dc.identifier.folioN3200798
dc.identifier.folio3200798
dc.identifier.issn1663-9812
dc.identifier.orcidhttps://orcid.org/0000-0002-8075-9812
dc.identifier.orcidhttps://orcid.org/0000-0002-6841-7182
dc.identifier.orcidhttps://orcid.org/0000-0002-7870-1056
dc.identifier.orcidhttps://orcid.org/0000-0001-6638-0817
dc.identifier.orcidhttps://orcid.org/0000-0002-9733-1118
dc.identifier.orcidhttps://orcid.org/0000-0002-0518-5556
dc.identifier.orcidhttps://orcid.org/0000-0002-1987-4600
dc.identifier.orcidhttps://orcid.org/0000-0001-9559-7660
dc.identifier.pmid36263116
dc.identifier.researcheridM-7714-2017
dc.identifier.researcheridKJL-9752-2024
dc.identifier.researcheridGLV-2034-2022
dc.identifier.researcheridHTL-5735-2023
dc.identifier.rorhttps://ror.org/02cafbr77
dc.identifier.rorhttps://ror.org/05y33vv83
dc.identifier.rorhttps://ror.org/028ynny55
dc.identifier.rorhttps://ror.org/013kx8n09
dc.identifier.rorhttps://ror.org/0166e9x11
dc.identifier.rorhttps://ror.org/01qq57711
dc.identifier.rorhttps://ror.org/04teye511
dc.identifier.scopusauthorid57930121700
dc.identifier.scopusauthorid57418401600
dc.identifier.scopusauthorid55921716700
dc.identifier.scopusauthorid55787389700
dc.identifier.scopusauthorid36757548900
dc.identifier.scopusauthorid36194557600
dc.identifier.scopusauthorid59576768500
dc.identifier.scopusauthorid24825037700
dc.identifier.scopusauthorid57217037645
dc.identifier.scopusauthorid57189040751
dc.identifier.urihttps://repositorio.udla.cl/handle/udla/1439
dc.language.isoeng
dc.publisherFRONTIERS MEDIA SA
dc.relation.fundingANID FONDECYT, (N3200798)
dc.relation.fundingPfizer, (67276851)
dc.relation.fundingPfizer
dc.relation.fundingAgencia Nacional de Investigación y Desarrollo, ANID, (NCN17-08)
dc.relation.fundingAgencia Nacional de Investigación y Desarrollo, ANID
dc.relation.fundingAgencia Nacional de Investigacion y Desarrollo (ANID, Chile) through the Millennium Science Initiative/Millennium Initiative for Collaborative Research on Bacterial Resistance, MICROB-R [NCN17-08]
dc.relation.fundingPfizer Global Medical Grant [67276851]
dc.relation.fundingANID FONDECYT [3200798]
dc.relation.isindexedbyWeb of Science
dc.relation.issn1663-9812
dc.rightsCreative Commons Attribution 4.0 International
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceFRONTIERS IN PHARMACOLOGY
dc.source.urihttps://doi.org/10.3389/fphar.2022.1007162
dc.subjectceftazidime/avibactam
dc.subjectcefotolozane/tazobactam
dc.subjectRND efflux pump
dc.subjectbaseline susceptibility
dc.subjectcarbapenem resistant Pseudomonas aeruginosa
dc.subject.oecd13 Ciencias Médicas y de la Salud
dc.subject.oecd23.1 Medicina Básica
dc.subject.oecd33.1.5 Farmacología y Farmacia
dc.titleRole of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
dc.title.alternativeRole of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
dc.typejournal article
dc.type.coarhttp://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.udla.catalogadorCBM
oaire.citation.titleFRONTIERS IN PHARMACOLOGY
oaire.citation.volume13
oaire.fundingReference.awardNumberN3200798
oaire.fundingReference.awardNumber3200798
oaire.fundingReference.funderNameAgencia Nacional de Investigación y Desarrollo (ANID)
udla.curacion.controljmvg
udla.oecd.area3 Ciencias Médicas y de la Salud
udla.oecd.discipline3.1.5 Farmacología y Farmacia
udla.oecd.subarea3.1 Medicina Básica

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
434.pdf
Size:
1.27 MB
Format:
Adobe Portable Document Format

Collections